Table 3. Cytotoxicity Evaluation (GI50, M) of Compounds 1-4 against Selected Tumor Cell Lines29.
| cell line | R =Me (1) | R = Et (2) | R = Pr (3) | R = iPr (4) |
|---|---|---|---|---|
| Leukemia | ||||
| CCRF-CEM | 2.21 × 10−7 | 5.36 × 10−7 | ||
| HL-60 × (TB) | 4.35 × 10−8 | 3.61 × 10−8 | 1.28 × 10−6 | 5.65 × 10−6 |
| K-562 | 2.95 × 10−8 | 9.52 × 10−7 | 9.32 × 10−7 | |
| MOLT-4 | <1.00 × 10−8 | 1.94 × 10−5 | 1.31 × 10−6 | |
| RPMI-8226 | <1.00 × 10−8 | 1.4 × 10−7 | 7.74 × 10−6 | |
| Nonsmall Cell Lung Cancer | ||||
| NCI-H460 | 6.31 × 10−7 | 2.44 × 10−7 | 2.67 × 10−7 | 6.45 × 10−6 |
| Colon Cancer | ||||
| HT29 | 1.60 × 10−7 | 5.4 × 10−8 | 9.58 × 10−6 | 5.76 × 10−6 |
| SW-620 | 1.24 × 10−7 | 9.0 × 10−8 | 1.21 × 10−6 | 4.71 × 10−6 |
| HCT 15 | 5.95 × 10−5 | 6.7 × 10−7 | >1.0 × 10−4 | 3.48 × 10−5 |
| Central Nervous System Cancer | ||||
| U251 | 8.24 × 10−7 | 1.6 × 10−6 | 7.24 × 10−6 | |
| SF268 | 7.47 × 10−5 | 2.2 × 10−7 | 1.61 × 10−6 | 1.78 × 10−5 |
| Melanoma | ||||
| LOX IMVI | 1.71 × 10−7 | 4.9 × 10−8 | <1.00 × 10−8 | 1.14 × 10−6 |
| Prostrate Cancer | ||||
| PC-3 | 4.36 × 10−8 | >1.0 × 10−4 | >1.0 × 10−4 | |
| Breast Cancer | ||||
| MCF-7 | >1 × 10−4 | 5.9 × 10−7 | 1.64 × 10−7 | |
| Renal Cancer | ||||
| ACHN | 2.42 × 10−5 | 4.5 × 10−7 | 1.52 × 10−5 | 7.39 × 10−6 |
| CAKI-1 | >1 × 10−4 | 1.25 × 10−7 | 3.76 × 10−7 | 4.25 × 10−6 |
| 786-0 | 1.28 × 10−8 | 5.58 × 10−6 | ||